As of June 18, 2026, Pyxis Oncology's top three insider holders are Inc Pfizer (TenPercentOwner, 5.95Mn shares), World Investments B.V. Bayer (Other, 2.74Mn shares), Lara Sullivan (President And Ceo, 2.40Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Inc Pfizer | - | 5,952,263 | 0 | 23 Mar, 2023 |
| John L Flavin | - | 413,015 | 0 | 28 Mar, 2024 |
| Freda C Lewis-Hall | - | 241,405 | 0 | 28 Mar, 2024 |
| Jakob Dupont | - | 38,741 | 0 | 28 Mar, 2024 |
| Rachel Humphrey | - | 96,805 | 0 | 28 Mar, 2024 |
| Asset Management, Lp Cormorant | - | 0 | 1,118,854 | 15 Oct, 2021 |
| Darren S Cline | - | 251,405 | 0 | 28 Mar, 2024 |
| Thomas Civik | - | 206,186 | 0 | 28 Mar, 2023 |
| Mark Chin | - | 66,831 | 0 | 04 Apr, 2022 |
| Lara Sullivan | President And Ceo | 2,403,882 | 0 | 18 Sep, 2023 |
| Pamela Ann Connealy | Cfo Coo | 0 | 2,314,886 | 27 Nov, 2024 |
| World Investments B.V. Bayer | - | 2,742,338 | 0 | 15 Oct, 2021 |
| Jay Feingold | Chief Medical Officer | 730,345 | 0 | 28 Mar, 2023 |
| Jitendra Wadhane | Prin Fin Acct Officer | 512,882 | 0 | 25 Mar, 2026 |
| Santhosh Palani | - | 6,000 | 0 | 07 Jun, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 24 Mar, 2026 | Michael A Metzger | Stock Option (Right to Buy) | A | 45,867 | $0.00 | 45,867 | D | A |
| 24 Mar, 2026 | Jitendra Wadhane | Common Stock | A | 109,461 | $0.00 | 512,882 | D | A |
| 24 Mar, 2026 | Santhosh Palani | Stock Option (Right to Buy) | A | 45,867 | $0.00 | 45,867 | D | A |
| 24 Mar, 2026 | Freda C Lewis-Hall | Stock Option (Right to Buy) | A | 45,867 | $0.00 | 45,867 | D | A |
| 24 Mar, 2026 | Jakob Dupont | Stock Option (Right to Buy) | A | 45,867 | $0.00 | 45,867 | D | A |
| 24 Mar, 2026 | Jitendra Wadhane | Common Stock | A | 109,461 | $0.00 | 512,882 | D | A |
| 24 Mar, 2026 | John L Flavin | Stock Option (Right to Buy) | A | 45,867 | $0.00 | 45,867 | D | A |
| 24 Mar, 2026 | Rachel Humphrey | Stock Option (Right to Buy) | A | 45,867 | $0.00 | 45,867 | D | A |
| 24 Mar, 2026 | Darren S Cline | Stock Option (Right to Buy) | A | 45,867 | $0.00 | 45,867 | D | A |
| 24 Mar, 2026 | Jitendra Wadhane | Stock Option (Right to Buy) | A | 262,635 | $0.00 | 262,635 | D | A |
| 24 Mar, 2026 | Jitendra Wadhane | Stock Option (Right to Buy) | A | 262,635 | $0.00 | 262,635 | D | A |
| 03 Feb, 2026 | Thomas Civik | Stock Option (Right to Buy) | A | 690,131 | $0.00 | 690,131 | D | A |
| 31 Mar, 2025 | Rachel Humphrey | Stock Option (Right to Buy) | A | 36,979 | $0.98 | 36,979 | D | A |
| 31 Mar, 2025 | Freda C Lewis-Hall | Stock Option (Right to Buy) | A | 36,979 | $0.98 | 36,979 | D | A |
| 31 Mar, 2025 | John L Flavin | Stock Option (Right to Buy) | A | 36,979 | $0.98 | 36,979 | D | A |
| 31 Mar, 2025 | Jitendra Wadhane | Stock Option (Right to Buy) | A | 263,782 | $0.98 | 263,782 | D | A |
| 31 Mar, 2025 | Santhosh Palani | Stock Option (Right to Buy) | A | 36,979 | $0.98 | 36,979 | D | A |
| 31 Mar, 2025 | Lara Sullivan | Stock Option (Right to Buy) | A | 918,308 | $0.98 | 918,308 | D | A |
| 31 Mar, 2025 | Darren S Cline | Stock Option (Right to Buy) | A | 36,979 | $0.98 | 36,979 | D | A |
| 31 Mar, 2025 | Thomas Civik | Stock Option (Right to Buy) | A | 36,979 | $0.98 | 36,979 | D | A |